9 Ways Estrogen Loss and HRT Use Both Affect Gallbladder Disease Risk — and How to Interpret the Evidence
Nobody warned me that the gallbladder was even on the list of things estrogen looks after. When the topic came up in a conversation about HRT, it felt like someone had moved the goalposts again — yet another system quietly affected by hormones that nobody thinks to mention until something goes wrong. The good news is that once you understand the mechanism, the evidence actually starts to make logical sense.
Learn more about Rose →Estrogen Directly Influences How the Liver Processes Cholesterol Into Bile
Estrogen regulates the activity of hepatic enzymes that determine how much cholesterol is secreted into bile versus recycled by the liver. When estrogen levels fall during perimenopause and menopause, this regulation loosens, and bile can become more cholesterol-saturated — a condition called biliary supersaturation that is the primary precursor to cholesterol gallstones. This is why postmenopausal women have higher gallstone prevalence than premenopausal women of the same age.
Gallbladder Motility Slows When Estrogen Declines
Estrogen supports the rhythmic contraction of the gallbladder, which ensures bile is regularly emptied into the small intestine rather than sitting and concentrating. Reduced estrogen is associated with slower gallbladder emptying — a condition known as gallbladder dysmotility — which allows cholesterol crystals more time to nucleate and grow into stones. This motility effect is separate from bile composition and compounds the overall risk.
Oral HRT Raises Gallstone Risk More Than Any Other Delivery Route
When estrogen is taken orally, it passes through the liver in high concentrations before entering general circulation — a process called the first-pass hepatic effect. This surge of estrogen at the liver increases cholesterol secretion into bile significantly, raising the lithogenicity of bile and the likelihood of stone formation. Large observational studies, including data from the Women's Health Initiative, consistently show that oral combined HRT roughly doubles the risk of gallbladder disease compared to no HRT.
Transdermal Estrogen Largely Bypasses the Liver and Carries a Much Lower Risk
Patches, gels, and sprays deliver estrogen through the skin directly into systemic circulation, avoiding the liver's first-pass processing almost entirely. Because the hepatic cholesterol secretion pathway is not triggered in the same concentrated way, transdermal estrogen does not produce the same bile supersaturation seen with oral doses. Current evidence suggests transdermal HRT carries a gallbladder disease risk that is either neutral or only minimally elevated compared to no treatment.
Progesterone and Progestogens Also Play a Role — and Not Always a Protective One
Progesterone receptors are present in gallbladder smooth muscle, and progesterone tends to reduce gallbladder contractility, slowing emptying further. Synthetic progestogens used in combined HRT may compound the gallbladder motility effects already caused by declining estrogen, particularly in women who already have sluggish gallbladder function. This is an area where micronised progesterone versus synthetic progestins may have meaningfully different profiles, though direct comparative gallbladder data remain limited.
Pre-existing Silent Gallstones Can Become Symptomatic After Starting Oral HRT
Many women carry small gallstones for years without symptoms — a state sometimes called 'silent cholelithiasis.' Oral HRT does not necessarily cause new stones in every user, but the shift in bile chemistry it produces can accelerate the growth of existing stones or tip the balance toward inflammation and obstruction. This explains why symptoms of gallbladder disease sometimes appear relatively soon after starting oral HRT, even though the stones themselves may have been forming for years.
Postmenopausal Weight Gain Independently Amplifies Gallstone Risk
The hormonal shifts of menopause are accompanied in many women by central adiposity, and visceral fat is independently associated with increased hepatic cholesterol production and biliary supersaturation. This means the gallbladder risk landscape during menopause is shaped by both estrogen loss itself and the metabolic changes that tend to accompany it, making it difficult to isolate any single cause. Managing weight during the menopause transition is relevant to gallbladder health as well as cardiovascular and metabolic outcomes.
The Timing of HRT Initiation Relative to Menopause May Modify Risk
There is emerging discussion, though not yet definitive evidence, that women who start HRT closer to the onset of menopause may have a different risk profile than those who begin it years later, partly because the metabolic and biliary environment shifts substantially over time in untreated postmenopause. Women who already have gallbladder changes from years of low estrogen before starting oral HRT may face a different risk calculation than those who transition directly. This mirrors the broader 'timing hypothesis' discussed in cardiovascular HRT research.
Gallbladder History Should Be Part of Any Honest HRT Conversation
Women with a personal history of gallstones or prior cholecystitis are typically advised to avoid oral estrogen specifically because of the hepatic first-pass mechanism, and many guidelines note this as a relative contraindication to oral — not transdermal — HRT. The distinction matters because it means a gallbladder history does not necessarily close the door on hormonal treatment, it shifts the conversation toward route of delivery. Any woman with gallbladder disease in her history is well-placed to raise this directly with her prescribing clinician before settling on an HRT formulation.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.